Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jun;26(3):e14234.
doi: 10.1111/tid.14234. Epub 2024 Jan 8.

The devil is in the details: Nuances of pre-emptive therapy for cytomegalovirus disease prevention in high-risk seropositive donors liver transplant recipients

Madeleine R Heldman  1 , Ajit P Limaye  2
Affiliations
Editorial

The devil is in the details: Nuances of pre-emptive therapy for cytomegalovirus disease prevention in high-risk seropositive donors liver transplant recipients

Madeleine R Heldman et al. Transpl Infect Dis. 2024 Jun.
No abstract available

Keywords: cytomegalovirus; ganciclovir; healthcare costs; liver transplant; pre‐emptive therapy; prophylaxis.

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Camus C, Poinot M, Pronier C, et al. Comparison of prophylaxis and preemptive strategy as cytomegalovirus prevention in liver transplant recipients. Transpl Infect Dis. 2023. TID‐23‐OrA‐163
    1. Singh N, Winston DJ, Razonable RR, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323(14):1378‐1387. doi:10.1001/jama.2020.3138
    1. Doss KM, Kling CE, Heldman MR,et al. Real‐world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high‐risk donor seropositive/recipient seronegative (D+R‐) liver transplant recipients (LTxR). Transpl Infect Dis. 2023:e14015. doi:10.1111/tid.14015
    1. Zamora D. Cytomegalovirus (CMV)‐specific T‐Cell and humoral immune responses in a randomized trial of preemptive antiviral therapy (PET) vs antiviral prophylaxis (PRO) after high‐Risk CMV D+R‐ liver transplant (LTx). Am J Transplant. 2023; 23(6) (Supp 1):S603.
    1. Kumar L, Murray‐Krezan C, Singh N, et al. A systematic review and meta‐analysis of optimized CMV preemptive therapy and antiviral prophylaxis for CMV disease prevention in CMV high‐risk (D+R‐) kidney transplant recipients. Transplant Direct. 2023;9(8):e1514. doi:10.1097/TXD.0000000000001514

MeSH terms